Finasteride vs Accutane (Isotretinoin): Head-to-Head Efficacy Comparison

Why These Two Drugs Get Compared

Patients searching for dermatologic medications often encounter both finasteride and isotretinoin on the same pharmacy shelf or telehealth platform, leading to confusion about their roles. The comparison is not apples-to-apples. Finasteride is a 5-alpha reductase inhibitor FDA-approved for androgenetic alopecia (AGA) in men at 1 mg daily. Isotretinoin is a systemic retinoid FDA-approved for severe recalcitrant nodular acne at weight-based dosing of 0.5-1 mg/kg/day.

The overlap that generates search queries is situational: young men aged 18-35 may deal with both hair thinning and persistent acne simultaneously, and both drugs carry hormonal or reproductive safety concerns that prompt comparison shopping. Some patients worry that treating one condition might worsen the other. Understanding how each drug works, what it achieves, and what it costs the body clarifies why choosing between them is rarely the right framing.

Mechanism of Action: Two Completely Different Targets

Finasteride competitively inhibits the type II isoenzyme of 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in hair follicles, prostate, and skin. By reducing serum DHT by approximately 64-71%, finasteride slows miniaturization of androgen-sensitive follicles on the vertex and frontal scalp.

Isotretinoin works through a different biological pathway entirely. As a retinoid (13-cis-retinoic acid), it binds nuclear retinoic acid receptors and reduces sebaceous gland size by up to 90%, decreases sebum production by roughly 80%, normalizes follicular keratinization, and exerts indirect anti-inflammatory effects. The cumulative dose of 120-150 mg/kg correlates with long-term remission because it achieves near-complete involution of the sebaceous gland apparatus.

These mechanisms do not overlap. A patient cannot substitute one for the other. Finasteride will not clear cystic acne, and isotretinoin will not reverse follicular miniaturization from AGA.

Efficacy Data: What the Landmark Trials Show

Finasteride for Androgenetic Alopecia

The key evidence comes from Kaufman et al. (1998), a 5-year randomized controlled trial of finasteride 1 mg daily in men with AGA. At 2 years, men taking finasteride showed a mean increase of 138 hairs in a 5.1 cm² target area compared to baseline, while the placebo group lost 72 hairs in the same area. That represents a net difference of 210 hairs per 5.1 cm² between groups. By year 5 to 48% of men treated with finasteride demonstrated visible hair regrowth as rated by independent expert panel review, and 42% had no further visible hair loss.

The drug works best for vertex thinning, with somewhat less reliable results at the frontal hairline. Response rates vary: roughly 80-90% of men experience stabilization of hair loss, while 50-65% see visible regrowth. Men under 30 with recent-onset thinning respond most robustly.

Isotretinoin for Severe Nodular Acne

Strauss et al. (1984) published the foundational dose-finding work establishing that a cumulative dose of 120-150 mg/kg produces durable remission of severe cystic acne. In their cohort, 85% of patients achieved complete or near-complete clearing by the end of a single 15-20 week course. The relapse rate at this cumulative dose was approximately 20-30%, with most relapses being milder than the original presentation.

Subsequent large-cohort studies have confirmed these numbers. A meta-analysis of isotretinoin outcomes found that 60-70% of patients remain in long-term remission after a single course, and those who relapse typically respond to a second course.

The speed of response differs markedly. Isotretinoin produces measurable sebum reduction within 2-4 weeks, visible acne improvement by 8-12 weeks, and maximal benefit by 16-20 weeks. This contrasts sharply with finasteride's 6-12 month timeline to visible hair changes.

Treatment Duration and Persistence of Effect

This distinction matters more than any other in comparing these drugs. Finasteride is a maintenance medication. Stop taking it, and hair loss resumes within 6-12 months as DHT levels normalize. The Kaufman trial confirmed that men who discontinued finasteride after 1 year lost their gains within 12 months. This means a 25-year-old starting finasteride for early AGA may take the drug for decades.

Isotretinoin is a finite course. Most patients complete 5-7 months of treatment and never require the drug again. The American Academy of Dermatology guidelines position isotretinoin as a one-time or two-time intervention, not a lifelong commitment. Even patients who relapse typically need only one additional course rather than indefinite therapy.

This creates fundamentally different risk-benefit calculations. With finasteride, you weigh ongoing low-grade risk exposure against ongoing benefit. With isotretinoin, you accept higher short-term risk for a potentially permanent outcome.

Side-Effect Profiles: Short-Term Intensity vs Long-Term Exposure

Finasteride Adverse Effects

The most discussed side effects of finasteride involve sexual function. In the Kaufman trial, 3.8% of finasteride-treated men reported decreased libido versus 2.1% on placebo. Erectile dysfunction occurred in 1.3% versus 0.7%. These differences are statistically significant but numerically modest. The vast majority of men reporting sexual side effects see resolution either while continuing the drug or after discontinuation.

The contested concept of "post-finasteride syndrome" (persistent sexual, neurological, and psychological symptoms after drug discontinuation) has generated significant patient anxiety. The NIH-funded Post-Finasteride Syndrome Foundation research acknowledges persistent symptoms in a small subset but notes that controlled prevalence data remain limited. The Endocrine Society does not recognize it as a formal diagnosis.

Isotretinoin Adverse Effects

Isotretinoin's side-effect burden is higher in absolute terms but time-limited. Nearly all patients experience mucocutaneous dryness: chapped lips (90%+), dry skin (80%+), dry eyes, and occasional nosebleeds. These resolve within weeks of stopping treatment.

The serious risks include teratogenicity (Category X; iPLEDGE REMS program mandatory for all prescriptions), transient elevation of triglycerides and liver enzymes (monitored with monthly labs), musculoskeletal pain, and rare cases of mood changes. The historical association between isotretinoin and depression has been challenged by large epidemiologic studies showing that severe acne itself carries higher depression risk than isotretinoin treatment, but monitoring remains standard practice.

Dr. James Del Rosso, past president of the American Acne and Rosacea Society, has stated: "Isotretinoin remains the most effective single agent we have for severe acne. The key is proper patient selection, dose optimization, and monitoring. When used appropriately, the benefit-risk ratio strongly favors treatment in patients with scarring or treatment-resistant disease."

Can You Take Both Simultaneously?

There is no pharmacokinetic interaction between finasteride and isotretinoin. They are metabolized by different cytochrome P450 pathways, and their mechanisms do not conflict. A young man with both androgenetic alopecia and severe nodular acne could theoretically take both drugs concurrently under physician supervision.

However, practical considerations exist. Both drugs require baseline and periodic lab monitoring (finasteride less formally, isotretinoin mandatorily). Isotretinoin can cause temporary telogen effluvium (diffuse hair shedding) in approximately 10-15% of patients during treatment. This is reversible and distinct from androgenetic alopecia, but it can alarm patients already anxious about hair loss. Starting finasteride first, establishing a stable baseline, and then adding isotretinoin may reduce diagnostic confusion about which drug is causing what.

Switching Between Treatments

The question "Can you switch from finasteride to isotretinoin?" reflects a misunderstanding of what each drug treats. You do not switch between them because they address different problems. A patient might stop finasteride because of side effects and no longer treat their hair loss, or they might complete isotretinoin and then start finasteride for a separate concern. But one does not replace the other therapeutically.

If a patient on finasteride develops acne (uncommon, since finasteride reduces DHT which typically reduces acne), isotretinoin could be added without discontinuing finasteride. Conversely, if a patient finishing isotretinoin notices accelerated hair thinning (possibly unmasked by resolution of the acne that previously occupied their attention), finasteride is an appropriate separate intervention.

Cost and Access Considerations

Generic finasteride 1 mg costs approximately $5-15/month at most pharmacies, making it one of the least expensive prescription medications in dermatology. It requires an annual prescription renewal and typically no lab monitoring beyond a baseline PSA in men over 40.

Generic isotretinoin costs $200-400/month without insurance for a typical course (varying by weight-based dose), though many insurance plans cover it for severe acne after documentation of failed prior therapies. The iPLEDGE REMS program adds administrative burden: monthly pregnancy tests for female patients, prescriber attestations, and pharmacy verification windows.

The total cost comparison over a lifetime favors isotretinoin: one 5-7 month investment versus potentially 30+ years of daily finasteride. A man starting finasteride at age 25 and continuing until age 60 would spend approximately $2,100-6,300 on the drug alone, while a single isotretinoin course totals $1,000-2,800.

Who Is the Right Candidate for Each Drug

Finasteride candidates: men with Norwood stage II-V androgenetic alopecia, ideally caught early (Norwood II-III), willing to commit to daily indefinite use, and comfortable with the low but real risk of sexual side effects. Women of childbearing potential cannot use finasteride due to teratogenic risk from handling crushed tablets; female-pattern hair loss has separate treatment algorithms.

Isotretinoin candidates: patients with severe nodular acne, acne producing scarring, or moderate acne that has failed adequate trials of topical retinoids, benzoyl peroxide, and oral antibiotics. The AAD guidelines recommend isotretinoin after failure of standard combination therapy, though some dermatologists advocate earlier use in scarring-prone phenotypes to prevent permanent damage.

Dr. Julie Harper, dermatologist and former president of the American Acne and Rosacea Society, has noted: "We do patients a disservice when we delay isotretinoin in someone who is clearly scarring. The earlier we intervene with definitive therapy, the less permanent damage accrues."

Monitoring Requirements Compared

Finasteride monitoring is minimal. No mandatory blood tests exist, though some clinicians check a baseline PSA and counsel patients about the drug's effect on PSA values (finasteride approximately halves PSA readings, which must be doubled for accurate prostate cancer screening interpretation). Follow-up involves clinical photography and subjective assessment every 6-12 months.

Isotretinoin monitoring is intensive. The standard protocol requires baseline and monthly fasting lipid panels, hepatic function tests, and CBC. Female patients require monthly pregnancy tests through iPLEDGE. Most dermatologists see isotretinoin patients monthly during the treatment course, then at 2-3 months post-completion to assess for early relapse.

The Bottom Line on Choosing

These drugs are not competitors. They serve entirely different clinical purposes. The patient who needs finasteride has hair follicles undergoing androgen-mediated miniaturization. The patient who needs isotretinoin has sebaceous glands producing pathologic quantities of sebum and generating inflammatory nodules. Some patients need both, sequentially or concurrently. Neither substitutes for the other, and framing the choice as "finasteride vs isotretinoin" mischaracterizes both drugs' clinical roles.

The only meaningful shared context is the young male patient facing both conditions simultaneously, where the question becomes one of sequencing and monitoring rather than choosing one over the other. Start with whichever condition is causing more distress or physical damage. For most patients, that means treating scarring acne first (isotretinoin for 5-7 months) and then addressing hair loss (finasteride indefinitely) once the acne course is complete.